Sakae Asanuma serves as Executive at Werewolf Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Sakae Asanuma has executed 3 insider transactions totaling $5.0M, demonstrating a bullish approach to their equity position. Their most recent transaction on May 4, 2021 involved purchasing 312,500 shares valued at $5.0M.
Sakae Asanuma currently holds 2,068,909 shares of Werewolf Therapeutics, Inc. (HOWL), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Sakae Asanuma has been a net buyer of HOWL stock. They have purchased $5.0M and sold $0 worth of shares.
Sakae Asanuma's most recent insider trade was on May 4, 2021, when they purchased 312,500 shares at $16.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| May 4, 2021 | HOWL | $0 | Conversion | 1,318,311 | $N/A | Discretionary |